Precision Biosciences Stock Price, News & Analysis

Precision BioSciences (DTIL) announced promising preclinical results for its ARCUS gene editing platform aimed at hepatitis B virus (HBV). Key findings include an 85% reduction in cccDNA and a 77% drop in HBsAg in HBV-infected human hepatocytes. The research also showed a 96% decrease in circulating HBsAg in animal models. Collaborating with Gilead Sciences and Acuitas Therapeutics, Precision plans to submit an IND application for its PBGENE-HBV candidate in 2024, marking a potential advancement in HBV treatment options.

Precision BioSciences (Nasdaq: DTIL) presented promising preclinical data on its ARCUS genome editing platform at the ASGCT conference (May 16-19, 2022). Key findings include:

• 98% knockdown of HAO1 protein in non-human primates related to Primary Hyperoxaluria Type 1.
• 85% degradation of Hepatitis B virus cccDNA and 77% reduction in HBsAg levels.
• Successful gene insertion approach for OTC deficiency in NHPs, with stable editing results.

The company plans to advance three product candidates to clinical trials over the next three years.

On May 6, 2022, Precision BioSciences (NASDAQ: DTIL) announced the grant of inducement awards under its 2021 Employment Inducement Incentive Award Plan. These awards consist of stock options totaling 401,905 shares, granted to four new employees who started on March 14, 2022. The options have an exercise price of $1.94, equal to the fair market value on the grant date, and a 10-year term with a vesting schedule. Precision BioSciences focuses on developing ARCUS-based gene editing therapies aimed at treating genetic and infectious diseases.

Precision BioSciences (Nasdaq: DTIL) reported a significant revenue decline to $3.3 million in Q1 2022 from $16.3 million in Q1 2021, primarily due to decreased income from its agreements with Servier and Lilly. R&D expenses decreased to $20 million from $25.6 million, while general and administrative costs rose to $10.7 million. The company posted a net loss of $28.2 million, compared to a loss of $18.7 million a year earlier. Key updates include anticipated progress in their CAR T programs and in vivo gene editing initiatives, with updates planned for June 2022.

Precision BioSciences (Nasdaq: DTIL) announced that four abstracts, including a collaborative research project, were accepted for presentation at the American Society of Gene & Cell Therapy (ASGCT) annual meeting from May 16-19, 2022, in Washington, D.C..

The presentations will focus on advancements in ARCUS^® gene editing therapies. Highlights include oral presentations on targeting Hepatitis B and gene targeting in macaques, as well as poster presentations on optimizing ARCUS nucleases for treating specific genetic diseases.

Precision BioSciences, Inc. (Nasdaq: DTIL) has announced its participation in the H.C. Wainwright Global Investment Conference on May 24, 2022. The company will also publish its financial results for the first quarter of 2022 and provide a business update on May 9, 2022. The conference presentation will be available on-demand starting at 7:00 AM ET. Precision BioSciences is focused on developing innovative CAR T therapies and gene editing platforms using its proprietary ARCUS technology.

Precision BioSciences (DTIL) announced significant advancements in gene editing and CAR T therapies. For 2021, revenues surged to $115.5 million, up from $24.3 million in 2020, attributed to strategic partnerships with Servier, Lilly, and iECURE. R&D expenses rose to $115.2 million from $98.1 million, reflecting investments in its innovative ARCUS platform. The net loss narrowed to $30.6 million, or $(0.52) per share. Going forward, the company aims to advance three in vivo programs to IND in three years and updates on allogenic CAR T clinical studies are anticipated in mid-2022.

Precision BioSciences, Inc. (Nasdaq: DTIL) will publish its financial results for Q4 and fiscal year 2021 on March 15, 2022, alongside a business update. The company focuses on developing ARCUS®-based ex vivo CAR T and in vivo gene editing therapies aimed at treating genetic and infectious diseases lacking adequate treatments. With its proprietary ARCUS platform, Precision BioSciences aims for therapeutic safety and control.

Atomwise, a leader in AI-driven small molecule drug discovery, has appointed David Thomson, Ph.D., as Chief Scientific Officer, alongside Jonathan Barr as Chief Financial Officer and Jeffrey Cerio, Pharm.D., J.D., as General Counsel. Dr. Thomson will spearhead the company's drug development strategy, focusing on enhancing their small molecule pipeline. His extensive experience includes leadership roles at Precision BioSciences and Shire. Barr brings expertise from Bridge Bio, where he managed significant capital raises. Cerio has a strong legal background from Moderna. The team aims to advance Atomwise's innovative drug discovery capabilities.